<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664664</url>
  </required_header>
  <id_info>
    <org_study_id>APD125-007</org_study_id>
    <nct_id>NCT00664664</nct_id>
  </id_info>
  <brief_title>Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare 2 doses of APD125 (20 mg and 40 mg) with placebo in&#xD;
      otherwise healthy adults with primary insomnia primarily with complaints of maintaining&#xD;
      sleep. Participants will be required to maintain a daily sleep dairy for up to 3 weeks while&#xD;
      on study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in subjective number of awakenings after sleep onset (sNAASO)</measure>
    <time_frame>During and after 2 weeks of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective total sleep time (sTST)</measure>
    <time_frame>During and after 2 weeks on study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective wake time after sleep onset (sWASO)</measure>
    <time_frame>During and after 2 weeks on study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective latency to sleep onset (sSLO)</measure>
    <time_frame>During and after 2 weeks on study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by changes from baseline in adverse events, vital signs, 12-lead ECGs, physical examinations, and clinical laboratory values.</measure>
    <time_frame>During and after 2 weeks on study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">744</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD125 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD125 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD125</intervention_name>
    <description>soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD125</intervention_name>
    <description>soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>soft gelatin capsule, daily dosing for up to 3 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, ages 18 to 65 years&#xD;
&#xD;
          -  Primary insomnia as defined in DSM-IV-TR, with predominant complaint of impaired sleep&#xD;
             maintenance and confirmed by patient reported sleep diaries&#xD;
&#xD;
          -  Generally good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any sleep disorder, other than primary insomnia (e.g., restless leg&#xD;
             syndrome, narcolepsy, sleep apnea, and disorders of REM/NREM sleep)&#xD;
&#xD;
          -  Any clinically significant medical condition, laboratory finding, or ECG finding&#xD;
&#xD;
          -  Pregnant and/or lactating females&#xD;
&#xD;
          -  History of substance abuse within 2 years or positive urine drug screen&#xD;
&#xD;
          -  Positive Hepatitis B/C results or HIV markers&#xD;
&#xD;
          -  History of treatment with an investigational drug within the last month&#xD;
&#xD;
          -  Recent travel involving crossing more than 3 time zones or plans to travel to another&#xD;
             time zone (&gt; 3 time zones) during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arena CT.gov Administrator</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arena Pharmaceuticals, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <disposition_first_submitted>December 16, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 16, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 24, 2020</disposition_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>sleep maintenance insomnia</keyword>
  <keyword>sleep quality</keyword>
  <keyword>non-restorative sleep</keyword>
  <keyword>multiple awakenings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

